GKOS
Glaukos Corporation · Healthcare
112.77
0.12%(+0.13)
Market Closed116.00
2.86%(+3.23)
After HoursLast Updated: — ET
52W L: $73.1652W H: $130.23
$109.60
CHG-2.05 (-1.84%)
H$113.87
L$95.85
VOL12M
GKOS (1h)
Glaukos Corporation · Healthcare
Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos Corporation (NYSE: GKOS) by 32.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 355,279 shares of the medical instruments supplier's stock after acquiring an additional 87,781 shares during
Glaukos Corporation (NYSE: GKOS - Get Free Report) CFO Alex Thurman sold 2,511 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.
Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.
Navratil Tomas
officer: CHIEF DEVELOPMENT OFFICER
1,146 SH @ $109.60
2026-04-02
Navratil Tomas
officer: CHIEF DEVELOPMENT OFFICER
1,831 SH @ $109.60
2026-04-02
Thurman Alex R.
officer: SVP & CHIEF FINANCIAL OFFICER
1,589 SH @ $109.60
2026-04-02
Gilliam Joseph E
officer: PRESIDENT & COO
3,169 SH @ $109.60
2026-04-02
Burns Thomas William
director, officer: CHAIRMAN & CEO
180,308 SH @ $0.00
2026-04-01
Burns Thomas William
director, officer: CHAIRMAN & CEO
180,308 SH @ $0.00
2026-04-01
Burns Thomas William
director, officer: CHAIRMAN & CEO
2,469 SH @ $109.60
2026-04-02
Burns Thomas William
director, officer: CHAIRMAN & CEO
7,468 SH @ $109.60
2026-04-02